Top

European Journal of Medical Research

Published in:

01-12-2011 | Research

Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy

Authors: P Velling, D Skowasch, S Pabst, E Jansen, I Tuleta, C Grohé

Published in: European Journal of Medical Research | Issue 9/2011

Abstract

Objective

Anti IgE treatment with omalizumab is efficacious in the treatment of patients suffering from allergic asthma, improving asthma control and improving quality of life. Furthermore, this approach could be beneficial for patients with concomitant atopic dermatitis. We assessed quality of life and asthma control in atopic patients with allergic asthma and concomitant atopic dermatitis versus those with asthma and without atopic dermatitis treated with omalizumab.

Methods

A total of 22 patients with severe allergic asthma were treated with omalizumab for 12 months. 13 patients with allergic asthma without concomitant atopic dermatitis (IgE 212 ± 224 IU/ml) and 9 patients with concomitant allergic asthma and atopic dermatitis (IgE 3,528 ± 2,723 IU/ml) were included. Asthma-related quality of life (AQLQ), atopic dermatitis related quality of life (DLQI), and asthma-related treatment were compared between both groups at baseline and after initiating omalizumab treatment.

Results

DLQI was significantly in favor of omalizumab after 2 months in the atopic dermatitis/asthma group (P = 0.01); AQLQ was improved after 6 months in the asthma group (P = 0.01), while no change was seen in AQLQ in the atopic dermatitis/asthma group (P = 0.12). Omalizumab controlled oral corticosteroid use more effective (P < 0.01) in patients with asthma and atopic dermatitis (in 9/9 cases) compared to patients with asthma alone (9/13). Baseline IgE as well as other factors do not predict response to omalizumab.

Conclusions

Omalizumab is effective in improving atopic dermatitis-related quality of life scores and modulates oral corticosteroid use in patients with concomitant asthma and atopic dermatitis in a positive fashion.

Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S, et al.: Low-dose anti-IgE in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2008,120(5):1223–1225.CrossRef

Bieber T: Atopic dermatitis. N Engl J Med 2008,358(14):1483–94. 10.1056/NEJMra074081PubMedCrossRef

Bousquet J, Cabreba P, Berkman N, Buhl R, Holgate S, Wenzel S, et al.: The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005,60(3):302–308. 10.1111/j.1398-9995.2004.00770.xPubMedCrossRef

Finlay AY, Khan GK: Dermatology life quality Index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology 1994,19(3):210–216. 10.1111/j.1365-2230.1994.tb01167.xPubMedCrossRef

Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P: The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Resp Med 2009,103(8):1098–1113. 10.1016/j.rmed.2009.03.008CrossRef

Humbert M, Beasly R, Ayres J, Slavin R, Hebert J, Bousquet J, et al.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005,60(3):309–316. 10.1111/j.1398-9995.2004.00772.xPubMedCrossRef

Incorvaia C, Pravettoni C, Mauro M, Yacoub MR, Tarantini F, Riario-Sforza GG: Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis 2008,69(2):78–80.PubMed

Krathen RA, Hsu S: Failure of Omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005,35(2):338–340.CrossRef

Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ: Treatment of recalcitrant atopic dermatitis with Omalizumab. J Am Acad Dermatol 2006,54(1):68–72. 10.1016/j.jaad.2005.09.030PubMedCrossRef

10.

Lim A, Luderschmidt S, Weidinger A, Schnopp C, Ring J, Hein R, Ollert M, Mempel M: The IgE repertoire in PBMCs of atopic patients is characterized by individual reaarangements without variable region of the heavy immunoglobulin chain bias. J Allergy Clin Immunol 2007,120(3):696–706. 10.1016/j.jaci.2007.05.035PubMedCrossRef

11.

Molimard M, de Blay F, Didier A, Le Gros V: Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008,102(1):71–76. 10.1016/j.rmed.2007.08.006PubMedCrossRef

12.

National Institutes of Health: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2007. Available from: http://www.ginaasthma.com

13.

Sheinkopf LE, Rafi AW, Do LAT, Katz RM, Klaustermeyer WB: Efficacy of Omalizumab in the treatment of atopic dermatitis: A pilot study. Allergy and Asthma Proceedings 2008,29(5):530–537. 10.2500/aap.2008.29.3160PubMedCrossRef

14.

Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I: Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006,5(1):168–170.CrossRef

Title: Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy
Authors: P Velling
D Skowasch
S Pabst
E Jansen
I Tuleta
C Grohé
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 9/2011
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/2047-783X-16-9-407

At a glance: The STEP trials

Springer Medicine

Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy

Abstract

Objective

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2011

Penicillium marneffei infection presenting as vulv-ulcer in an HIV-infected woman

TB or not TB? Difficulties in the diagnosis of tuberculosis in HIV-negative immigrants to Germany

Investigation of the flexibility of bronchoscopes

Depression and religiosity in older age

Long survival of primary diffuse leptomeningeal gliomatosis following radiotherapy and temozolomide: case report and literature review

Feasibility and safety of long-term photodynamic therapy (PDT) in the palliative treatment of patients with hilar cholangiocarcinoma